HSBC Holdings’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $457K | Buy |
19,922
+1,506
| +8% | +$33.5K | ﹤0.01% | 2261 |
|
|
2025
Q4 | $479K | Buy |
18,416
+1,316
| +8% | +$31.3K | ﹤0.01% | 2340 |
|
|
2025
Q3 | $443K | Sell |
17,100
-4,585
| -21% | -$113K | ﹤0.01% | 2168 |
|
|
2025
Q2 | $515K | Sell |
21,685
-1,254
| -5% | -$31.6K | ﹤0.01% | 2144 |
|
|
2025
Q1 | $565K | Buy |
22,939
+7,864
| +52% | +$188K | ﹤0.01% | 2015 |
|
|
2024
Q4 | $290K | Sell |
15,075
-154
| -1% | -$2.7K | ﹤0.01% | 2511 |
|
|
2024
Q3 | $228K | Sell |
15,229
-13,504
| -47% | -$231K | ﹤0.01% | 2534 |
|
|
2024
Q2 | $812K | Buy |
28,733
+12,275
| +75% | +$349K | ﹤0.01% | 1757 |
|
|
2024
Q1 | $481K | Buy |
16,458
+5,478
| +50% | +$168K | ﹤0.01% | 2123 |
|
|
2023
Q4 | $368K | Buy |
10,980
+1,114
| +11% | +$32.6K | ﹤0.01% | 2188 |
|
|
2023
Q3 | $303K | Buy |
9,866
+2,846
| +41% | +$103K | ﹤0.01% | 2213 |
|
|
2023
Q2 | $283K | Sell |
7,020
-7,729
| -52% | -$320K | ﹤0.01% | 2182 |
|
|
2023
Q1 | $599K | Buy |
14,749
+5,260
| +55% | +$209K | ﹤0.01% | 1972 |
|
|
2022
Q4 | $366K | Buy |
9,489
+1,474
| +18% | +$71.7K | ﹤0.01% | 2430 |
|
|
2022
Q3 | $434K | Buy |
8,015
+3,074
| +62% | +$171K | ﹤0.01% | 2233 |
|
|
2022
Q2 | $289K | Sell |
4,941
-4,625
| -48% | -$303K | ﹤0.01% | 2651 |
|
|
2022
Q1 | $730K | Buy |
+9,566
| New | +$638K | ﹤0.01% | 2154 |
|
|
2021
Q1 | – | Sell |
-20,260
| Closed | -$1.2M | – | 3027 |
|
|
2020
Q4 | $1.2M | Buy |
20,260
+3,598
| +22% | +$211K | ﹤0.01% | 1584 |
|
|
2020
Q3 | $1.01M | Buy |
+16,662
| New | +$968K | ﹤0.01% | 1540 |
|
|
2020
Q2 | – | Sell |
-6,137
| Closed | -$206K | – | 2811 |
|
|
2020
Q1 | $206K | Buy |
+6,137
| New | +$255K | ﹤0.01% | 2284 |
|
|
2019
Q4 | – | Sell |
-34,872
| Closed | -$1.33M | – | 3152 |
|
|
2019
Q3 | $1.33M | Buy |
+34,872
| New | +$1.39M | ﹤0.01% | 1806 |
|
|
2018
Q4 | – | Sell |
-52,471
| Closed | -$2.57M | – | 2685 |
|
|
2018
Q3 | $2.57M | Buy |
+52,471
| New | +$2.27M | ﹤0.01% | 1375 |
|
|
2017
Q1 | – | Sell |
-7,405
| Closed | -$239K | – | 2465 |
|
|
2016
Q4 | $239K | Buy |
+7,405
| New | +$247K | ﹤0.01% | 2411 |
|
|
2015
Q2 | – | Sell |
-2,497
| Closed | -$221K | – | 2232 |
|
|
2015
Q1 | $221K | Sell |
2,497
-56
| -2% | -$5.68K | ﹤0.01% | 1890 |
|
|
2014
Q4 | $226K | Buy |
+2,553
| New | +$241K | ﹤0.01% | 1670 |
|
Other funds holding PCRX
DPCM
VPM
VCM
HSBC Holdings's PCRX Position: Q1 2026 in Review
HSBC Holdings increased its Pacira BioSciences (PCRX) stake by 8.2% in Q1 2026, buying an estimated $33.5K and bringing the position to 19,922 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #2261.
HSBC Holdings first reported a position in PCRX in Q4 2014 and has held it in 25 quarters since. The position peaked at $2.57M in Q3 2018. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- HSBC Holdings held 19,922 shares of Pacira BioSciences worth $457K as of Q1 2026.
- HSBC Holdings bought 1,506 Pacira BioSciences shares in Q1 2026, an estimated $33.5K.
- Pacira BioSciences made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2261 holding.
- HSBC Holdings first reported a position in Pacira BioSciences in Q4 2014 and has held it in 25 quarters since.
- HSBC Holdings's Pacira BioSciences position peaked at $2.57M in Q3 2018.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.